Supramolecular crafting of self-assembling camptothecin prodrugs with enhanced efficacy against primary cancer cells

Theranostics

Volumn 6, Issue 7, 2016, Pages 1065-1074

  Su, Hao ^a   Zhang, Pengcheng ^a   Cheetham, Andrew G ^a   Koo, Jin Mo ^a   Lin, Ran ^a   Masood, Asad ^a   Schiapparelli, Paula ^b   Quiñones Hinojosa, Alfredo ^b,d   Cui, Honggang ^a,c,d  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Brain cancer; CPT Prodrug; High potency; Nanomedicine; Peptides; Self assembly

Indexed keywords

CAMPTOTHECIN; IRINOTECAN; ANTINEOPLASTIC AGENT; PRODRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; SUPRAMOLECULAR CHEMISTRY; BRAIN TUMOR; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; SOLUBILITY; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; PRODRUGS; SOLUBILITY;

EID: 84979530123     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.15420     Document Type: Article

References (71)

1. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008; 7: 255-70.
2. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci. 2000; 89: 145-54.
3. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6: 789-802.
4. Bala V, Rao SS, Boyd BJ, Prestidge CA. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release. 2013; 172: 48-61.
5. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66: 10048-56.
6. Roger E, Lagarce F, Benoit JP. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm. 2011; 79: 181-8.
7. Thakur R, Sivakumar B, Savva M. Thermodynamic Studies and Loading of 7-Ethyl-10-hydroxycamptothecin into Mesoporous Silica Particles MCM-41 in Strongly Acidic Solutions. J Phys Chem B. 2010; 114: 5903-11.
8. Kim SH, Kaplan JA, Sun Y, Shieh A, Sun HL, Croce CM, et al. The Self-Assembly of Anticancer Camptothecin-Dipeptide Nanotubes: A Minimalistic and High Drug Loading Approach to Increased Efficacy. Chem-Eur J. 2015; 21: 101-5.
9. Lu JQ, Liu C, Wang PC, Ghazwani M, Xu JN, Huang YX, et al. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin. Biomaterials. 2015; 62: 176-87.
10. Li XQ, Wen HY, Dong HQ, Xue WM, Pauletti GM, Cai XJ, et al. Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism. Chem Commun. 2011; 47: 8647-9.
11. Newton M, Wetzstein G, Sullivan D. Topoisomerase I Inhibitors -The Camptothecins. Cancer Grow Prog-Dor. 2011; 13: 103-23.
12. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The Current Status of Camptothecin Analogs as Antitumor Agents. J Natl Cancer I. 1993; 85: 271-91.
13. Eloy JO, de Souza MC, Petrilli R, Barcellos JPA, Lee RJ, Marchetti JM. Liposomes as carriers of hydrophilic small molecule drugs: Strategies to enhance encapsulation and delivery. Colloid Surface B. 2014; 123: 345-63.
14. Cheetham AG, Zhang PC, Lin YA, Lock LL, Cui HG. Supramolecular Nanostructures Formed by Anticancer Drug Assembly. J Am Chem Soc. 2013; 135: 2907-10.
15. Lin R, Cheetham AG, Zhang PC, Lin YA, Cui HG. Supramolecular filaments containing a fixed 41% paclitaxel loading. Chem Commun. 2013; 49: 4968-70.
16. Su H, Koo JM, Cui HG. One-component nanomedicine. J Control Release. 2015; 219: 383-95.
17. Zhao F, Ma ML, Xu B. Molecular hydrogels of therapeutic agents. Chem Soc Rev. 2009; 38: 883-91.
18. MacKay JA, Chen MN, McDaniel JR, Liu WG, Simnick AJ, Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater. 2009; 8: 993-9.
19. Desmaele D, Gref R, Couvreur P. Squalenoylation: A generic platform for nanoparticular drug delivery. J Control Release. 2012; 161: 609-18.
20. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Deliver Rev. 2012; 64: 37-48.
21. Lin R, Cui H. Supramolecular nanostructures as drug carriers. Curr Opin Chem Eng. 2015; 7: 75-83.
22. Jeannine MC, Kaplan DL. Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery. Bioconjug Chem. 2015.
23. Bhattacharyya J, Bellucci JJ, Weitzhandler I, McDaniel JR, Spasojevic I, Li XH, et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat Commun. 2015; 6.
24. Zhang SY, Zou J, Elsabahy M, Karwa A, Li A, Moore DA, et al. Poly(ethylene oxide)-block-polyphosphester-based paclitaxel conjugates as a platform for ultra-high paclitaxel-loaded multifunctional nanoparticles. Chem Sci. 2013; 4: 2122-6.
25. Zou J, Zhang FW, Zhang SY, Pollack SF, Elsabahy M, Fan JW, et al. Poly(ethylene oxide)-block-Polyphosphoester-graft-Paclitaxel Conjugates with Acid-Labile Linkages as a pH-Sensitive and Functional Nanoscopic Platform for Paclitaxel Delivery. Adv Healthc Mater. 2014; 3: 441-8.
26. Tong R, Cheng JJ. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. Angew Chem Int Edit. 2008; 47: 4830-4.
27. Tong R, Cheng JJ. Ring-Opening Polymerization-Mediated Controlled Formulation of Polylactide-Drug Nanoparticles. J Am Chem Soc. 2009; 131: 4744-54.
28. Gao Y, Kuang Y, Guo ZF, Guo ZH, Krauss IJ, Xu B. Enzyme-Instructed Molecular Self-assembly Confers Nanofibers and a Supramolecular Hydrogel of Taxol Derivative. J Am Chem Soc. 2009; 131: 13576-+.
29. Li XM, Li JY, Gao YA, Kuang Y, Shi JF, Xu B. Molecular Nanofibers of Olsalazine Form Supramolecular Hydrogels for Reductive Release of an Anti-inflammatory Agent. J Am Chem Soc. 2010; 132: 17707-9.
30. Tan XY, Li BB, Lu XG, Jia F, Santori C, Menon P, et al. Light-Triggered, Self-Immolative Nucleic Acid-Drug Nanostructures. J Am Chem Soc. 2015; 137: 6112-5.
31. Wang M, Alberti K, Sun S, Arellano CL, Xu QB. Combinatorially Designed Lipid-like Nanoparticles for Intracellular Delivery of Cytotoxic Protein for Cancer Therapy. Angew Chem Int Edit. 2014; 53: 2893-8.
32. Bastings MMC, Koudstaal S, Kieltyka RE, Nakano Y, Pape ACH, Feyen DAM, et al. A Fast pH-Switchable and Self-Healing Supramolecular Hydrogel Carrier for Guided, Local Catheter Injection in the Infarcted Myocardium. Adv Healthc Mater. 2014; 3: 70-8.
33. Khlebtsov N, Bogatyrev V, Dykman L, Khlebtsov B, Staroverov S, Shirokov A, et al. Analytical and Theranostic Applications of Gold Nanoparticles and Multifunctional Nanocomposites. Theranostics. 2013; 3: 167-80.
34. Kumar R, Kulkarni A, Nagesha DK, Sridhar S. In Vitro Evaluation of Theranostic Polymeric Micelles for Imaging and Drug Delivery in Cancer. Theranostics. 2012; 2: 714-22.
35. Abbadi S, Rodarte JJ, Abutaleb A, Lavell E, Smith CL, RuffW, et al. Glucose-6-phosphatase Is a Key Metabolic Regulator of Glioblastoma Invasion. Mol Cancer Res. 2014; 12: 1547-59.
36. Chaichana KL, Jusue-Torres I, Lemos AM, Gokaslan A, Cabrera-Aldana EE, Ashary A, et al. The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors? J Neuro-Oncol. 2014; 120: 625-34.
37. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncology. 2014; 16: 113-22.
38. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009; 110: 156-62.
39. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 2005; 435: 773-8.
40. Hamley IW. Peptide fibrillization. Angew Chem Int Edit. 2007; 46: 8128-47.
41. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. P Natl Acad Sci USA. 2008; 105: 12128-33.
42. Henne WA, Doorneweerd DD, Hilgenbrink AR, Kularatne SA, Low PS. Synthesis and activity of a folate peptide camptothecin prodrug. Bioorg Med Chem Lett. 2006; 16: 5350-5.
43. Kularatne SA, Venkatesh C, Santhapuram HKR, Wang K, Vaitilingam B, Henne WA, et al. Synthesis and Biological Analysis of Prostate-Specific Membrane Antigen-Targeted Anticancer Prodrugs. J Med Chem. 2010; 53: 7767-77.
44. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Cl Lab Sci. 2006; 43: 143-81.
45. Cheetham AG, Ou YC, Zhang PC, Cui HG. Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles. Chem Commun. 2014; 50: 6039-42.
46. Zhang QQ, He JL, Zhang MZ, Ni PH. A polyphosphoester-conjugated camptothecin prodrug with disulfide linkage for potent reduction-triggered drug delivery. J Mater Chem B. 2015; 3: 4922-32.
47. Hu XL, Hu JM, Tian J, Ge ZS, Zhang GY, Luo KF, et al. Polyprodrug Amphiphiles: Hierarchical Assemblies for Shape-Regulated Cellular Internalization, Trafficking, and Drug Delivery. J Am Chem Soc. 2013; 135: 17617-29.
48. Wang H, Tang L, Tu CL, Song ZY, Yin Q, Yin LC, et al. Redox-Responsive, Core-Cross-Linked Micelles Capable of On-Demand, Concurrent Drug Release and Structure Disassembly. Biomacromolecules. 2013; 14: 3706-12.
49. Liu JY, Liu WE, Weitzhandler I, Bhattacharyya J, Li XH, Wang J, et al. Ring-Opening Polymerization of Prodrugs: A Versatile Approach to Prepare Well-Defined Drug-Loaded Nanoparticles. Angew Chem Int Edit. 2015; 54: 1002-6.
50. Lee MH, Yang Z, Lim CW, Lee YH, Dongbang S, Kang C, et al. Disulfide-Cleavage-Triggered Chemosensors and Their Biological Applications. Chem Rev. 2013; 113: 5071-109.
51. Versluis F, Marsden HR, Kros A. Power struggles in peptide-amphiphile nanostructures. Chem Soc Rev. 2010; 39: 3434-44.
52. Cavalli S, Albericio F, Kros A. Amphiphilic peptides and their cross-disciplinary role as building blocks for nanoscience. Chem Soc Rev. 2010; 39: 241-63.
53. Hamley IW. Self-assembly of amphiphilic peptides. Soft Matter. 2011; 7: 4122-38.
54. Fleury F, Ianoul A, Berjot M, Feofanov A, Alix AJP, Nabiev I. Camptothecin-binding site in human serum albumin and protein transformations induced by drug binding. Febs Lett. 1997; 411: 215-20.
55. Fleury F, Kudelina I, Nabiev I. Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. Febs Lett. 1997; 406: 151-6.
56. Person RV, Monde K, Humpf HU, Berova N, Nakanishi K. A New Approach in Exciton-Coupled Circular-Dichroism (Eccd) -Insertion of an Auxiliary Stereogenic Center. Chirality. 1995; 7: 128-35.
57. Watanabe K, Akagi K. Helically assembled pi-conjugated polymers with circularly polarized luminescence. Sci Technol Adv Mat. 2014; 15.
58. Aida T, Meijer EW, Stupp SI. Functional Supramolecular Polymers. Science. 2012; 335: 813-7.
59. Cui HG, Webber MJ, Stupp SI. Self-Assembly of Peptide Amphiphiles: From Molecules to Nanostructures to Biomaterials. Biopolymers. 2010; 94: 1-18.
60. Haines-Butterick L, Rajagopal K, Branco M, Salick D, Rughani R, Pilarz M, et al. Controlling hydrogelation kinetics by peptide design for three-dimensional encapsulation and injectable delivery of cells. P Natl Acad Sci USA. 2007; 104: 7791-6.
61. Gopal R, Park JS, Seo CH, Park Y. Applications of Circular Dichroism for Structural Analysis of Gelatin and Antimicrobial Peptides. Int J Mol Sci. 2012; 13: 3229-44.
62. Korevaar PA, Newcomb CJ, Meijer EW, Stupp SI. Pathway Selection in Peptide Amphiphile Assembly. J Am Chem Soc. 2014; 136: 8540-3.
63. Ortony JH, Newcomb CJ, Matson JB, Palmer LC, Doan PE, Hoffman BM, et al. Internal dynamics of a supramolecular nanofibre. Nat Mater. 2014; 13: 812-6.
64. Tantakitti F, Boekhoven J, Wang X, Kazantsev RV, Yu T, Li J, et al. Energy landscapes and functions of supramolecular systems. Nat Mater. 2016.
65. Meijer JT, Roeters M, Viola V, Lowik DWPM, Vriend G, van Hest JCM. Stabilization of peptide fibrils by hydrophobic interaction. Langmuir. 2007; 23: 2058-63.
66. Meijer JT, Henckens MJAG, Minten IJ, Lowik DWPM, van Hest JCM. Disassembling peptide-based fibres by switching the hydrophobic-hydrophilic balance. Soft Matter. 2007; 3: 1135-7.
67. Smith CL, Chaichana KL, Lee YM, Lin BJ, Stanko KM, O'Donnell T, et al. Pre-Exposure of Human Adipose Mesenchymal Stem Cells to Soluble Factors Enhances Their Homing to Brain Cancer. Stem Cell Transl Med. 2015; 4: 239-51.
68. Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, et al. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemoth Pharm. 2006; 58: 165-72.
69. Schoemaker NE, Kuppens IELM, Huinink WWT, Lefebvre P, Beijnen JH, Assadourian S, et al. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemoth Pharm. 2005; 55: 263-70.
70. Choi KY, Swierczewska M, Lee S, Chen XY. Protease-Activated Drug Development. Theranostics. 2012; 2: 156-78.
71. Chen K, Chen XY. Integrin Targeted Delivery of Chemotherapeutics. Theranostics. 2011; 1: 189-200.